PNC taps Coinbase to create crypto trading offering for bank customers
PNC will use Coinbase's institutional 'crypto-as-a-service' platform to develop an offering that will allow PNC clients to buy, hold and sell cryptocurrencies. The Pittsburgh-based financial institution will also offer certain banking services to Coinbase.
The PNC-Coinbase partnership is a stark shift for the banking sector, which crypto companies at one point had accused of being hostile to their industry. Lawmakers earlier this year held a hearing to scrutinise US banks and their regulators in response to claims they deny services to particular industries.
Republicans and Democrats agreed that banks may be improperly denying services to some clients, but disagreed on the root cause.
The banking industry has fiercely resisted accusations that it denies services based on ideological reasons. It has instead argued that onerous, outdated and opaque rules make it difficult for banks to sometimes provide services, or explain why they cannot.
The partnership announcement comes as US President Donald Trump and his administration have embraced cryptocurrencies and enacted industry-friendly policies. Trump signed a law on Friday to create a regulatory regime for US dollar-pegged cryptocurrencies known as stablecoins, a major milestone for the digital asset sector, which has long lobbied for such a framework.
Several banks, including Bank of America and Citibank, have said that they are exploring issuing their own stablecoins.
'Partnering with Coinbase accelerates our ability to bring innovative, crypto financial solutions to our clients,' William Demchak, PNC CEO, said. 'This collaboration enables us to meet growing demand for secure and streamlined access to digital assets on PNC's trusted platform.' REUTERS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
International Business Times
an hour ago
- International Business Times
Appeals Court Questions Trump's Use of Emergency Powers to Justify Tariffs
A US federal appeals court raised serious doubts about President Donald Trump's authority to impose broad tariffs under emergency powers. During a hearing in Washington, D.C., judges questioned whether the International Emergency Economic Powers Act (IEEPA) grants the president the legal right to impose tariffs on allied nations like Canada, China, and Mexico. Trump had used IEEPA to introduce what he called "reciprocal" tariffs in April and further increased them in February. The case now before the U.S. Court of Appeals for the Federal Circuit was brought by five small businesses and 12 Democratic-led states. They argue that Trump overstepped his powers and that only Congress has the constitutional right to set tariffs and taxes. Government lawyer Brett Shumate defended Trump's move, saying IEEPA gives the president broad authority in economic emergencies, including regulating imports. But Judge Jimmie Reyna responded, "IEEPA doesn't even mention tariffs." Several judges appeared skeptical throughout the 90-minute hearing, which concluded without a ruling date. The outcome of this case could have major implications. Trump, who made tariffs a key trade tool during his second term, claims they helped address unfair trade practices and boosted U.S. manufacturing. He cited the U.S. trade deficit and illegal fentanyl imports as justification. However, critics argue these reasons do not constitute an "extraordinary threat" under the law. Earlier this year, a lower court also ruled that IEEPA does not support tariffs based on long-term trade imbalances. The appeals court has allowed the tariffs to stay in place while legal challenges continue. With customs duties now generating over $100 billion in revenue this fiscal year, tariffs have become a significant funding source. Still, economists warn that they raise consumer prices and disrupt supply chains. The Trump administration argues that removing tariff power could harm trade negotiations, although recent deals with the EU, Japan, and others have moved forward. Trump has warned of further tariff hikes on countries not reaching new trade deals by August 1. The final decision in this case is likely to head to the U.S. Supreme Court if either side loses.
International Business Times
an hour ago
- International Business Times
Asian Markets Tumble After Trump's Tariffs Announcement; Investors Watch US. Jobs Report Closely
Investors felt the jitters as Asian markets dropped on Friday after U.S. President Donald Trump signed an executive order imposing tariffs ranging between 10% and 41% on imports from countries such as India, Taiwan, Thailand, South Korea, and Turkey. South Korea's KOSPI dropped 3%, Taiwan's TWII slipped 0.9% to its lowest in two months, Japan's Nikkei was off 0.4%, and MSCI's broadest index of Asia-Pacific shares outside Japan lost 0.7%, also marking a 1.8% decline for the week. Chinese blue chips were little changed, and Hong Kong's Hang Seng inched higher by 0.2%. Freepik The tremors were also felt in European markets, where futures for EUROSTOXX 50 fell 0.2%. Futures for the Nasdaq and the S&P 500 fell 0.2% in reaction to Amazon's earnings, which fell short of expectations and caused its shares to drop 6.6% in extended trading. Apple provided a little boost to sentiment, up 2.4% on strong revenue guidance. Tariffs Create Uncertainty Ahead of Fed Decision The new tariffs range from 25% on Indian goods and 20% on Taiwanese exports to 19% on Thai imports. The new tariff rate for South Korea is 15% down from the earlier announced 25%. Canadian goods not covered under the USMCA are subject to a new 35% tariff rate, up from 25%. Mexico was relieved as it got a 90-day break to negotiate further. Markets reacted with caution. Wall Street gave up early gains on Thursday. The Dow dropped 0.75%, the S&P 500 ended down more than 0.3%, and the Nasdaq closed slightly in the red. Fresh U.S. inflation data suggested that prices were rising, in part because of tariffs. Fed fund futures now show just a 39% probability of a rate cut in September, down from 65% before the Fed stuck to its announced rates on Wednesday. Dollar Gains, Bond Yields Steady Amid Caution The dollar advanced as traders trimmed rate-cut wagers. The dollar's index rose to 100.1, its highest in two months, with a 2.5% weekly gain, the most since 2022. The yen weakened 0.8% to 150.7 per dollar after the Bank of Japan kept rates on hold and sounded a cautious note. The Canadian dollar was steady even as tariffs increased. The yield on the 10-year United States Treasury note edged up to 4.374%. Commodities Mixed as Oil Holds Steady, Gold Loses Ground Oil prices remained flat after a 1% decline on Wednesday. U.S. crude rose 0.1% to $69.36 a barrel, and Brent gained 0.2% to $71.84. On the spot market, gold was down slightly, to $3,286 an ounce, as investors balanced a flood of safe-haven demand against rising yields and a stronger dollar.
International Business Times
an hour ago
- International Business Times
Trump Demands Drug Price Cuts in Letters to 17 Pharma Giants Summary
US President Donald Trump has sent letters to 17 major pharmaceutical companies demanding they cut prescription drug prices in the United States. The letters, released Thursday by the White House, outline his plan to match U.S. prices with those in other developed countries. President Donald Trump addessses the nation after U.S. bombed Iran's nuclear facilities X Trump recently signed an executive order requiring drugmakers to offer "most-favored-nation" pricing. This means companies must sell medications to U.S. patients at the lowest price they offer elsewhere. If drug companies do not comply, Trump warned the government could import cheaper alternatives or take other steps. Companies that received the letters include Pfizer, Eli Lilly, Johnson & Johnson, Merck, Sanofi, and AstraZeneca. Trump had previously criticized earlier proposals from the industry, saying they prioritized profits over patient care. He also demanded that drugmakers return any excess profits made by raising prices overseas to compensate American taxpayers. Shares of major pharmaceutical firms fell after the announcement. Pfizer, Eli Lilly, and Gilead each dropped by around 2%, while a broader index of drug stocks declined 3%. Trump also suggested a system where companies can sell drugs directly to patients, bypassing middlemen, but only if they agree to international pricing rules. The president gave drugmakers a deadline of September 29 to respond with binding commitments. Health experts are skeptical that companies will meet Trump's demands. Some analysts believe the proposals are unlikely to result in immediate price changes, describing them as more political pressure than enforceable policy. Still, several companies, including Pfizer and Novartis, said they are open to working with the administration. Pfizer confirmed its ongoing talks with Trump officials to improve access and affordability for U.S. patients. U.S. drug prices remain among the highest in the world, with patients often paying nearly three times more than those in other developed countries. Drugmakers argue that sharp price cuts could harm innovation, but Trump insists bold action is needed to protect Americans from high costs.
